Advanced in Olfactory Neuroblastoma

Dr. William T. Curry

Neurosurgery
Massachusetts General Physicians Organization Inc
55 Fruit St, 
Boston, MA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Advanced in Olfactory Neuroblastoma
Massachusetts General Physicians Organization Inc
55 Fruit St, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

William Curry is a Neurosurgery provider in Boston, Massachusetts. Dr. Curry is rated as an Advanced provider by MediFind in the treatment of Olfactory Neuroblastoma. His top areas of expertise are Glioblastoma, Astrocytoma, Meningioma, Awake Craniotomy, and Septoplasty. Dr. Curry is currently accepting new patients.

His clinical research consists of co-authoring 155 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 6 articles in the study of Olfactory Neuroblastoma.

Specialties
Neurosurgery
Licenses
Neurological Surgery in MA
Hospital Affiliations
Massachusetts General Hospital
North Shore Medical Center -
Brigham And Women's Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Neighborhood
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
Tufts
  • HMO

Locations

MASSACHUSETTS GENERAL PHYSICIANS ORGANIZATION INC
55 Fruit St, Boston, MA 02114

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Long-term Follow-up of Subjects Treated With CAR T Cells
Long-term Follow-up of Subjects Treated With CAR T Cells
Enrollment Status: Recruiting
Publish Date: October 01, 2025
Intervention Type: Diagnostic test, Procedure
A Phase II Study of the Safety and Efficacy of SVN53-67/M57-KLH (SurVaxM) in Survivin-Positive Newly Diagnosed Glioblastoma
A Phase II Study of the Safety and Efficacy of SVN53-67/M57-KLH (SurVaxM) in Survivin-Positive Newly Diagnosed Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: October 10, 2025
Intervention Type: Biological, Drug, Other
Study Drugs: Montanide ISA 51 VG, Sargramostim, SVN53-67/M57-KLH Peptide Vaccine, Temozolomide
Study Phase: Phase 2
A Multicenter Phase 2 Study of Oncolytic Polio/Rhinovirus Recombinant (Lerapolturev) in Recurrent WHO Grade IV Malignant Glioma Patients
A Multicenter Phase 2 Study of Oncolytic Polio/Rhinovirus Recombinant (Lerapolturev) in Recurrent WHO Grade IV Malignant Glioma Patients
Enrollment Status: Completed
Publish Date: July 11, 2025
Intervention Type: Biological, Drug
Study Drug: Oncolytic Polio/Rhinovirus Recombinant Vaccine
Study Phase: Phase 2
A Phase 2, Open-label, Single-arm Study Evaluating the Efficacy, Safety and Tolerability of Lerapolturev (PVSRIPO) and the Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of Patients With Recurrent Glioblastoma
A Phase 2, Open-label, Single-arm Study Evaluating the Efficacy, Safety and Tolerability of Lerapolturev (PVSRIPO) and the Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: June 05, 2025
Intervention Type: Biological
Study Drugs: PVSRIPO, Pembrolizumab
Study Phase: Phase 2
A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND # 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND # 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
Enrollment Status: Terminated
Publish Date: January 24, 2025
Intervention Type: Biological, Drug
Study Drugs: HSPPC-96, Bevacizumab
Study Phase: Phase 2
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Enrollment Status: Suspended
Publish Date: April 03, 2024
Intervention Type: Biological
Study Phase: Phase 3
A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy
A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy
Enrollment Status: Completed
Publish Date: April 28, 2020
Intervention Type: Radiation, Other, Biological
Study Phase: Not Applicable
A Phase I Study of Vaccination With Lethally Irradiated Glioma Cells Mixed With GM-K562 Cells in Patients Undergoing Craniotomy For Recurrent Tumor
A Phase I Study of Vaccination With Lethally Irradiated Glioma Cells Mixed With GM-K562 Cells in Patients Undergoing Craniotomy For Recurrent Tumor
Enrollment Status: Completed
Publish Date: June 22, 2017
Intervention Type: Biological
Study Phase: Phase 1
View 7 Less Clinical Trials

155 Total Publications

Barriers and Facilitators to Topical Fluoride Varnish Application in Well-Child Visits.
Barriers and Facilitators to Topical Fluoride Varnish Application in Well-Child Visits.
Journal: JDR clinical and translational research
Published: June 17, 2025
Similar Doctors
Experienced in Olfactory Neuroblastoma
Dr. Wenya L. Bi
Neurosurgery
Experienced in Olfactory Neuroblastoma
Dr. Wenya L. Bi
Neurosurgery

Brigham And Womens Physicians Organization Inc

75 Francis St, 
Boston, MA 
 (2.7 miles away)
617-732-5500
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Wenya Bi is a Neurosurgery provider in Boston, Massachusetts. Dr. Bi is rated as an Elite provider by MediFind in the treatment of Olfactory Neuroblastoma. Her top areas of expertise are Meningioma, Brain Tumor, Astrocytoma, Awake Craniotomy, and Nerve Decompression. Dr. Bi is currently accepting new patients.

Experienced in Olfactory Neuroblastoma
Dr. Carl B. Heilman
Neurosurgery
Experienced in Olfactory Neuroblastoma
Dr. Carl B. Heilman
Neurosurgery

New England Medical Center Group Practice Inc

800 Washigton St, 
Boston, MA 
 (0.9 miles away)
617-636-7399
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Carl Heilman is a Neurosurgery provider in Boston, Massachusetts. Dr. Heilman is rated as a Distinguished provider by MediFind in the treatment of Olfactory Neuroblastoma. His top areas of expertise are Meningioma, Hydrocephalus, Acoustic Neuroma, Endoscopic Transnasal Transsphenoidal Surgery, and Mastoidectomy. Dr. Heilman is currently accepting new patients.

Experienced in Olfactory Neuroblastoma
Dr. Joel Z. Passer
Neurosurgery
Experienced in Olfactory Neuroblastoma
Dr. Joel Z. Passer
Neurosurgery

Lahey Clinic Inc

1 Essex Ctr Dr, 
Peabody, MA 
 (13.6 miles away)
978-538-4000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Joel Passer is a Neurosurgery provider in Peabody, Massachusetts. Dr. Passer is rated as an Advanced provider by MediFind in the treatment of Olfactory Neuroblastoma. His top areas of expertise are Meningioma, Radiation Induced Meningioma, Chronic Subdural Hematoma, Awake Craniotomy, and Gamma Knife Radiosurgery. Dr. Passer is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Curry's expertise for a condition
ConditionClose
View All 18 Distinguished Conditions
View All 16 Advanced Conditions
View All 33 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile